References

 

  1.  Abdelhak, A., et al., Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker? Front Neurol, 2019. 10: p. 280.
  2. Abdelhak, A., et al., Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep, 2018. 8(1): p. 14798.
  3. Abu-Rumeileh S, et al., The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. Alzheimers Res Ther. 2018 Jan 11;10(1):3. doi: 10.1186/s13195-017-0331-1.
  4. Abu-Rumeileh, S., et al., Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study. J Alzheimers Dis, 2018. 66(2): p. 551-563.
  5. Abu-Rumeileh, S., et al., Revisiting the Cerebrospinal Fluid Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus: The Bologna Pro-Hydro Study. J Alzheimers Dis, 2019. 68(2): p. 723-733.
  6. Abu-Rumeileh, S., et al., Sporadic Fatal Insomnia in Europe: Phenotypic Features and Diagnostic Challenges. Ann Neurol, 2018. 84(3): p. 347-360.
  7. Aeinehband S, et al. Complement component C3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis. PLoS One. 2015 Apr 2;10(4):e0122048.
  8. Ahlgren E, et al. Association between Plasma Homocysteine Levels and Neuronal Injury in HIV Infection. PLoS One. 2016 Jul 21;11(7):e0158973.
  9. Akhtar, R.S. and T. Mano, High serum neurofilament light chain predicts a worse fate in early parkinsonism. Neurology, 2019. 92(13): p. 595-596.
  10. Al Nimer F, et al. Comparative Assessment of the Prognostic Value of Biomarkers in Traumatic Brain Injury Reveals an Independent Role for Serum Levels of Neurofilament Light. PLoS One. 2015 Jul 2;10(7).
  11. Al Nimer F, et al. Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 7;3(1):e191.
  12. Al Shweiki, M.R., et al., Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. J Psychiatr Res, 2019. 113: p. 137-140.
  13. Albanese M, et al. Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression. J Neuroinflammation. 2016 Feb 10;13:36.
  14. Alcolea D, et al. CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration. Neurology. 2017 Jul 11;89(2):178-188.
  15. Alcolea D, et al., CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration. Neurology. 2017 Jul 11;89(2):178-188. doi: 10.1212/WNL.0000000000004088. Epub 2017 Jun 7.
  16. Al-Khaled M. Serum neurofilament light as diagnostic biomarker for acute cerebral ischemia: a promising tool. Eur J Neurol. 2018 Apr;25(4):609. doi: 10.1111/ene.13588. Epub 2018 Feb.
  17. Al-Temaimi R, et al., Remyelination modulators in multiple sclerosis patients. Exp Mol Pathol. 2017 Dec;103(3):237-241. doi: 10.1016/j.yexmp.2017.11.004. Epub 2017 Nov 8.
  18. Alves G, et al. Neurofilament light: A heavyweight diagnostic biomarker in neurodegenerative parkinsonism? Neurology. 2017 Mar 7;88(10):922-923.
  19. Anckarsäter R, et al. Non-neurological surgery and cerebrospinal fluid biomarkers for neuronal and astroglial integrity. J Neural Transm (Vienna). 2014 Jun;121(6):649-53.
  20. Anderson AM, et al. Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals. J Neurovirol. 2017 Feb;23(1):106-112.
  21. Anderson, A.M., et al., Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapy. J Neurovirol, 2018. 24(6): p. 695-701.
  22. Andres-Benito, P., et al., YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression. Aging (Albany NY), 2018. 10(9): p. 2367-2382.
  23. Anesten B, et al. Blood-brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV. Neurol Neuroimmunol Neuroinflamm. 2016 Nov 9;3(6).
  24. Angel TE, et al. The cerebrospinal fluid proteome in HIV infection: change associated with disease severity. Clin Proteomics. 2012 Mar 20;9(1):3.
  25. Anzalone, A.J., et al., Blood Biomarkers of Sports-Related Concussion in Pediatric Athletes. Clin J Sport Med, 2019.
  26. Arrambide G, et al. Neurofilament light chain level is a weak risk factor for the development of MS. Neurology. 2016 Sep 13;87(11):1076-84.
  27. Arulsamy A, et al., Evaluation of early chronic functional outcomes and their relationship to pre-frontal cortex and hippocampal pathology following moderate-severe traumatic brain injury. Behav Brain Res. 2018 Apr 10;348:127-138. doi: 10.1016/j.bbr.2018.04.009. [Epub ahead of print]
  28. Axelsson M, et al. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis. J Neurol. 2011 May;258(5):882-8.
  29. Axelsson M, et al. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler. 2014 Jan;20(1):43-50.
  30. Axelsson M, et al., Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barré syndrome: A pilot study. Acta Neurol Scand. 2018 Apr 6. doi: 10.1111/ane.12927. [Epub ahead of print]
  31. Bacioglu M, et al. Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. Neuron. 2016 Jul 20;91(2):494-496.
  32. Bacioglu M, et al. Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. Neuron. 2016 Jul 6;91(1):56-66.
  33. Bäckström DC, et al. Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease. JAMA Neurol. 2015 Oct;72(10):1175-82.
  34. Bagnato S, et al. Prolonged Cerebrospinal Fluid Neurofilament Light Chain Increase in Patients with Post-Traumatic Disorders of Consciousness. J Neurotrauma. 2017 Aug 15;34(16):2475-2479.
  35. Bagnato S, et al., Prolonged Cerebrospinal Fluid Neurofilament Light Chain Increase in Patients with Post-Traumatic Disorders of Consciousness. J Neurotrauma. 2017 Aug 15;34(16):2475-2479. doi: 10.1089/neu.2016.4837. Epub 2017 Jun 8.
  36. Barro C, et al., Fluid biomarker and electrophysiological outcome measures for progressive MS trials. Mult Scler. 2017 Oct;23(12):1600-1613. doi: 10.1177/1352458517732844.
  37. Barro, C., et al., Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain, 2018. 141(8): p. 2382-2391.
  38. Bateman, R.J., et al., Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report. J Prev Alzheimers Dis, 2019. 6(3): p. 169-173.
  39. Bech S, et al. Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. Parkinsonism Relat Disord. 2012 Jan;18(1):69-72.
  40. Benatar, M., et al., Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol, 2018. 84(1): p. 130-139.
  41. Bendlin BB, et al. CSF T-Tau/Aβ42 predicts white matter microstructure in healthy adults at risk for Alzheimer’s disease.PLoS One. 2012;7(6):e37720.
  42. Bergman J, et al. Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. Neurol Neuroimmunol Neuroinflamm. 2016 Aug 2;3(5).
  43. Bergman L, et al., Blood-based cerebral biomarkers in preeclampsia: Plasma concentrations of NfL, tau, S100B and NSE during pregnancy in women who later develop preeclampsia – A nested case control study. PLoS One. 2018 May 2;13(5):e0196025. doi: 10.1371/journal.pone.0196025. eCollection 2018.
  44. Bergman, L., et al., Blood-based cerebral biomarkers in preeclampsia: Plasma concentrations of NfL, tau, S100B and NSE during pregnancy in women who later develop preeclampsia – A nested case control study. PLoS One, 2018. 13(5): p. e0196025.
  45. Bernick, C., et al., Longitudinal Performance of Plasma Neurofilament Light and Tau in Professional Fighters: The Professional Fighters Brain Health Study. J Neurotrauma, 2018. 35(20): p. 2351-2356.
  46. Bettcher BM, et al., Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer’s Disease Pathology and Neuronal Damage. J Alzheimers Dis. 2018;62(1):385-397. doi: 10.3233/JAD-170602.
  47. Bhan, A., et al., Neurofilaments and 10-year follow-up in multiple sclerosis. Mult Scler, 2018. 24(10): p. 1301-1307.
  48. Bischof A, et al. Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy. Ann Rheum Dis. 2017 Jul 25
  49. Bischof A, et al., Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy. Ann Rheum Dis. 2017 Jul 25. pii: annrheumdis-2017-212045. doi: 10.1136/annrheumdis-2017-212045. [Epub ahead of print] No abstract available.
  50. Bjerke M, et al. Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer’s disease. J Alzheimers Dis. 2011;27(3):665-76.
  51. Bjerke M, et al. Cerebrovascular Biomarker Profile Is Related to White Matter Disease and Ventricular Dilation in a LADIS Substudy. Dement Geriatr Cogn Dis Extra. 2014 Oct 21;4(3):385-94.
  52. Bjerke M, et al. Subcortical vascular dementia biomarker pattern in mild cognitive impairment. Dement Geriatr Cogn Disord. 2009;28(4):348-56.
  53. Blennow K. A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood. Neurol Ther. 2017 Jul;6(Suppl 1):15-24.
  54. Boesen, M.S., et al., Increased cerebrospinal fluid chitinase 3-like 1 and neurofilament light chain in pediatric acquired demyelinating syndromes. Mult Scler Relat Disord, 2018. 24: p. 175-183.
  55. Brureau A, et al. NF-L in cerebrospinal fluid and serum is a biomarker of neuronal damage in an inducible mouse model of neurodegeneration. Neurobiol Dis. 2017 Aug;104:73-84.
  56. Brureau A, et al., NF-L in cerebrospinal fluid and serum is a biomarker of neuronal damage in an inducible mouse model of neurodegeneration. Neurobiol Dis. 2017 Aug;104:73-84. doi: 10.1016/j.nbd.2017.04.007. Epub 2017 Apr 6.
  57. Burman J, et al. Assessing tissue damage in multiple sclerosis: a biomarker approach. Acta Neurol Scand. 2014 Aug;130(2):81-9.
  58. Byrne LM, et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease: a retrospective cohort analysis. Lancet Neurol. 2017 Aug;16(8):601-609.
  59. Byrne LM, et al., Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease: a retrospective cohort analysis. Lancet Neurol. 2017 Aug;16(8):601-609. doi: 10.1016/S1474-4422(17)30124-2. Epub 2017 Jun 7.
  60. Byrne, L.M., et al., Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington’s disease. Sci Transl Med, 2018. 10(458).
  61. Chatterjee P, et al., Association of Plasma Neurofilament Light Chain with Neocortical Amyloid-β Load and Cognitive Performance in Cognitively Normal Elderly Participants. J Alzheimers Dis. 2018;63(2):479-487. doi: 10.3233/JAD-180025.
  62. Cheng WH, et al., Age at injury and genotype modify acute inflammatory and neurofilament-light responses to mild CHIMERA traumatic brain injury in wild-type and APP/PS1 mice. Exp Neurol. 2018 Mar;301(Pt A):26-38. doi: 10.1016/j.expneurol.2017.12.007. Epub 2017 Dec 18.
  63. Clement A, et al. Cerebrospinal fluid neurofilament light chain as a biomarker of neurodegeneration in the Tg4510 and MitoPark mouse models. Neuroscience. 2017 Jun 23;354:101-109.
  64. Clouston, S.A.P., et al., Posttraumatic stress disorder and total amyloid burden and amyloid-beta 42/40 ratios in plasma: Results from a pilot study of World Trade Center responders. Alzheimers Dement (Amst), 2019. 11: p. 216-220.
  65. Constantinescu R, et al. Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies. J Neuroimmunol. 2017 May 15;306:25-30.
  66. Constantinescu R, et al. Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis. Eur J Neurol. 2016 Apr;23(4):796-806.
  67. Constantinescu R, et al. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson’s disease and atypical Parkinsonian disorders. Parkinsonism Relat Disord. 2010 Feb;16(2):142-5.
  68. Constantinescu R, et al. Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington’s disease. Parkinsonism Relat Disord. 2009 Mar;15(3):245-8.
  69. Constantinescu R, et al. Light subunit of neurofilament triplet protein in the cerebrospinal fluid after subthalamic nucleus stimulation for Parkinson’s disease. Acta Neurol Scand. 2011 Sep;124(3):206-10.
  70. Cuello, J.P., et al., Neurofilament light chain levels in pregnant multiple sclerosis patients: a prospective cohort study. Eur J Neurol, 2019.
  71. Cysique, L.A., et al., HIV brain latency as measured by CSF BcL11b relates to disrupted brain cellular energy in virally suppressed HIV infection. Aids, 2019. 33(3): p. 433-441.
  72. Dalla Costa, G., et al., Prognostic value of serum neurofilaments in patients with clinically isolated syndromes. Neurology, 2019. 92(7): p. e733-e741.
  73. Dalla Costa, G., et al., Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients. Ann Neurol, 2019. 85(4): p. 606-610.
  74. Damasceno, A., et al., Clinical and MRI correlates of CSF neurofilament light chain levels in relapsing and progressive MS. Mult Scler Relat Disord, 2019. 30: p. 149-153.
  75. Danielson, M., et al., Effects of methylprednisolone on blood-brain barrier and cerebral inflammation in cardiac surgery-a randomized trial. J Neuroinflammation, 2018. 15(1): p. 283.
  76. de Flon P, et al. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology. 2016 Jul 12;87(2):141-7.
  77. de Flon, P., et al., Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial. Acta Neurol Scand, 2019. 139(5): p. 462-468.
  78. De Marchis GM, et al., Serum neurofilament light chain in patients with acute cerebrovascular events. Eur J Neurol. 2018 Mar;25(3):562-568. doi: 10.1111/ene.13554. Epub 2018 Jan 24.
  79. Deisenhammer, F., et al., The Cerebrospinal Fluid in Multiple Sclerosis. Front Immunol, 2019. 10: p. 726.
  80. Disanto G, et al.  Swiss Multiple Sclerosis Cohort Study Group. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017 Jun;81(6):857-870.
  81. Disanto G, et al. International Clinically Isolated Syndrome Study Group.. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):126-9.
  82. Donker Kaat, L., et al., Serum neurofilament light chain in progressive supranuclear palsy. Parkinsonism Relat Disord, 2018. 56: p. 98-101.
  83. Duering, M., et al., Serum Neurofilament Light Chain Levels Are Related to Small Vessel Disease Burden. J Stroke, 2018. 20(2): p. 228-238.
  84. Edén A, et al. Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment. PLoS One. 2016 Jun 13;11(6):e0157160.
  85. Edwards, K.R., et al., Neurofilament light chain as an indicator of exacerbation prior to clinical symptoms in multiple sclerosis. Mult Scler Relat Disord, 2019. 31: p. 59-61.
  86. Ehler, J., et al., The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy – A prospective, pilot observational study. PLoS One, 2019. 14(1): p. e0211184.
  87. Evered L, et al. Cerebrospinal Fluid Biomarker for Alzheimer Disease Predicts Postoperative Cognitive Dysfunction.Anesthesiology. 2016 Feb;124(2):353-61.
  88. Evered L, et al., Association of Changes in Plasma Neurofilament Light and Tau Levels With Anesthesia and Surgery: Results From the CAPACITY and ARCADIAN Studies. JAMA Neurol. 2018 May 1;75(5):542-547. doi: 10.1001/jamaneurol.2017.4913.
  89. Evers KS, et al., Neurofilament as Neuronal Injury Blood Marker in Preeclampsia. Hypertension. 2018 Jun;71(6):1178-1184. doi: 10.1161/HYPERTENSIONAHA.117.10314. Epub 2018 Apr 23.
  90. Evers, K.S., et al., Neurofilament as Neuronal Injury Blood Marker in Preeclampsia. Hypertension, 2018. 71(6): p. 1178-1184.
  91. Eyjolfsdottir H, et al. Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer’s disease patients: application of a second-generation encapsulated cell biodelivery device. Alzheimers Res Ther. 2016 Jul 7;8(1):30.
  92. Farotti L, et al. Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson’s disease. Expert Rev Mol Diagn. 2017 Aug;17(8):771-780.
  93. Feneberg E, et al., Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology. 2018 Jan 2;90(1):e22-e30. doi: 10.1212/WNL.0000000000004761. Epub 2017 Dec 6.
  94. Fialová L, et al. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis. J Neuroimmunol. 2013 Sep 15;262(1-2):113-20.
  95. Fialova L, et al., Neurofilaments and tau proteins in cerebrospinal fluid and serum in dementias and neuroinflammation. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017 Sep;161(3):286-295. doi: 10.5507/bp.2017.038. Epub 2017 Sep 25.
  96. Foiani MS, et al., Plasma tau is increased in frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2018 Feb 13. pii: jnnp-2017-317260. doi: 10.1136/jnnp-2017-317260. [Epub ahead of print]
  97. Fortea, J., et al., Plasma and CSF biomarkers for the diagnosis of Alzheimer’s disease in adults with Down syndrome: a cross-sectional study. Lancet Neurol, 2018. 17(10): p. 860-869.
  98. Fyfe, I., Neurofilament makes light of MS treatment monitoring. Nat Rev Neurol, 2019. 15(4): p. 188.
  99. Gaetani, L., et al., Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry, 2019.
  100. Gaiani A, et.al. Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease. JAMA Neurol. 2017 Mar 6.
  101. Gangishetti, U., et al., Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease. Alzheimers Res Ther, 2018. 10(1): p. 98.
  102. Gattringer T, et al., Serum neurofilament light is sensitive to active cerebral small vessel disease. Neurology. 2017 Nov 14;89(20):2108-2114. doi: 10.1212/WNL.0000000000004645. Epub 2017 Oct 18.
  103. Gavhed D, et al. Biomarkers in the cerebrospinal fluid and neurodegeneration in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2009 Dec 15;53(7):1264-70.
  104. Gifford, K.A., et al., The 12-Word Philadelphia Verbal Learning Test Performances in Older Adults: Brain MRI and Cerebrospinal Fluid Correlates and Regression-Based Normative Data. Dement Geriatr Cogn Dis Extra, 2018. 8(3): p. 476-491.
  105. Gill, J., et al., Glial fibrillary acidic protein elevations relate to neuroimaging abnormalities after mild TBI. Neurology, 2018. 91(15): p. e1385-e1389.
  106. Gille, B., et al., Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis. Neuropathol Appl Neurobiol, 2019. 45(3): p. 291-304.
  107. Giovannoni, G., Peripheral blood neurofilament light chain levels: the neurologist’s C-reactive protein? Brain, 2018. 141(8): p. 2235-2237.
  108. Gisslén M, et al. Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. EBioMedicine. 2015 Nov 22;3:135-40.
  109. Goossens J, et al., Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration. Alzheimers Res Ther. 2018 Mar 20;10(1):31. doi: 10.1186/s13195-018-0364-0.
  110. Grahn A, et al. Cerebrospinal fluid biomarkers in patients with varicella-zoster virus CNS infections. J Neurol. 2013 Jul;260(7):1813-21.
  111. Gravesteijn, G., et al., Serum Neurofilament light correlates with CADASIL disease severity and survival. Ann Clin Transl Neurol, 2019. 6(1): p. 46-56.
  112. Gudmundsson P, et al. Is there a CSF biomarker profile related to depression in elderly women? Psychiatry Res. 2010 Apr 30;176(2-3):174-8.
  113. Gunnarsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol. 2011 Jan;69(1):83-9.
  114. Håkansson I, et al. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis. Eur J Neurol. 2017 Mar 6.
  115. Hakansson, I., et al., Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis. J Neuroinflammation, 2018. 15(1): p. 209.
  116. Halawa I, et al., Seizures, CSF neurofilament light and tau in patients with subarachnoid haemorrhage. Acta Neurol Scand. 2018 Feb;137(2):199-203. doi: 10.1111/ane.12873. Epub 2017 Nov 21.
  117. Hall S, et al. CSF biomarkers and clinical progression of Parkinson disease. Neurology. 2015 Jan 6;84(1):57-63.
  118. Hall S, et al. Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson’s Disease. Mov Disord. 2016 Jun;31(6):898-905.
  119. Hampel H, et al., Alzheimer’s disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ1-42, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40. Alzheimer Precision Medicine Initiative (APMI). Alzheimers Dement. 2018 Apr;14(4):492-501. doi: 10.1016/j.jalz.2017.11.015. Epub 2018 Jan 9.
  120. Hansson O, et al. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. Neurology. 2017 Mar 7;88(10):930-937.
  121. Herbert MK, et al. CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders. Front Neurol. 2015 May 5;6:91.
  122. Hjalmarsson C, et al. Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke. J Cent Nerv Syst Dis. 2014 May 19;6:51-8.
  123. Höglund K, et al. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration. Transl Psychiatry. 2017 Jan 10;7(1).
  124. Holmoy, T., et al., Vitamin D supplementation and neurofilament light chain in multiple sclerosis. Acta Neurol Scand, 2019. 139(2): p. 172-176.
  125. Hossain, I., et al., Early Levels of Glial Fibrillary Acidic Protein and Neurofilament Light Protein in Predicting the Outcome of Mild Traumatic Brain Injury. J Neurotrauma, 2019. 36(10): p. 1551-1560.
  126. Hrubesova, K., et al., Search for biomarkers of Alzheimer’s disease: Recent insights, current challenges and future prospects. Clin Biochem, 2019.
  127. Hubertus, V., N. Marklund, and P. Vajkoczy, Management of concussion in soccer. Acta Neurochir (Wien), 2019. 161(3): p. 425-433.
  128. Hyun, J.W., et al., Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis. Mult Scler, 2019: p. 1352458519840757.
  129. Idland AV, et al. CSF neurofilament light levels predicthippocampal atrophy in cognitively healthy older adults. Neurobiol Aging. 2017 Jan;49:138-144.
  130. Illan-Gala, I., et al., CSF sAPPbeta, YKL-40, and NfL along the ALS-FTD spectrum. Neurology, 2018. 91(17): p. e1619-e1628.
  131. Isgren A, et al. Markers of neuroinflammation and neuronal injury in bipolar disorder: Relation to prospective clinical outcomes. Brain Behav Immun. 2017 Oct;65:195-201.
  132. Isgren A, et al., Markers of neuroinflammation and neuronal injury in bipolar disorder: Relation to prospective clinical outcomes.Brain Behav Immun. 2017 Oct;65:195-201. doi: 10.1016/j.bbi.2017.05.002. Epub 2017 May 5.
  133. Iverson, G.L., et al., Serum Neurofilament Light Is Elevated Differentially in Older Adults with Uncomplicated Mild Traumatic Brain Injuries. J Neurotrauma, 2019.
  134. Jabbari E, et al. Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers. J Neurol Neurosurg Psychiatry. 2017 Jun 9.
  135. Jabbari E, et al., Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers. J Neurol Neurosurg Psychiatry. 2017 Oct;88(10):883-888. doi: 10.1136/jnnp-2017-315857. Epub 2017 Jun 9. Review.
  136. Jabbari, E., et al., Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry, 2019.
  137. Jakobsson J, et al. Elevated concentrations of neurofilament light chain in the cerebrospinal fluid of bipolar disorder patients.Neuropsychopharmacology. 2014 Sep;39(10):2349-56.
  138. Janelidze S, et al. Increased CSF biomarkers of angiogenesis in Parkinson disease. Neurology. 2015 Nov 24;85(21):1834-42.
  139. Jennum PJ, et al. Cerebrospinal fluid biomarkers of neurodegeneration are decreasedor normal in narcolepsy. Sleep. 2016 Sep 9. pii: sp-00139-16.
  140. Jeppsson A, et al. Amyloid mis-metabolism in idiopathic normal pressure hydrocephalus. Fluids Barriers CNS. 2016 Jul 29;13(1):13.
  141. Jeppsson A, et al. Idiopathic normal-pressure hydrocephalus: pathophysiology and diagnosis by CSF biomarkers. Neurology. 2013 Apr 9;80(15):1385-92.
  142. Jespersen S, et al. Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study. BMC Infect Dis. 2016 Apr 21;16:176.
  143. Jessen Krut J, et al. Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients. PLoS One. 2014 Feb 11;9(2):e88591.
  144. Johnson EB TRACK-HD Study Group et al., Neurofilament light protein in blood predicts regional atrophy in Huntington disease. Neurology. 2018 Feb 20;90(8):e717-e723. doi: 10.1212/WNL.0000000000005005. Epub 2018 Jan 24.
  145. Jonsson M, et al. Cerebrospinal fluid biomarkers of white matter lesions – cross-sectional results from the LADIS study. Eur J Neurol. 2010 Mar;17(3):377-82.
  146. Jonsson M, et al. Low cerebrospinal fluid sulfatide predicts progression of white matter lesions: The LADIS study. Dement Geriatr Cogn Disord. 2012;34(1):61-7.
  147. Joseph, J.R., et al., Elevated markers of brain injury as a result of clinically asymptomatic high-acceleration head impacts in high-school football athletes. J Neurosurg, 2018: p. 1-7.
  148. Kalatha, T., et al., Does cognitive dysfunction correlate with neurofilament light polypeptide levels in the CSF of patients with multiple sclerosis? J Int Med Res, 2019: p. 300060519840550.
  149. Kalm M et al. Serum concentrations of the axonal injury marker neurofilament light protein are not influenced by blood-brain barrier permeability. Brain Res. 2017 Aug 1;1668:12-19.
  150. Kalm M, et al., Serum concentrations of the axonal injury marker neurofilament light protein are not influenced by blood-brain barrier permeability. Brain Res. 2017 Aug 1;1668:12-19. doi: 10.1016/j.brainres.2017.05.011. Epub 2017 May 15.
  151. Kanata, E., et al., Cerebrospinal fluid neurofilament light in suspected sporadic Creutzfeldt-Jakob disease. J Clin Neurosci, 2019. 60: p. 124-127.
  152. Kawata K, et al., A Preliminary Report on Brain-Derived Extracellular Vesicle as Novel Blood Biomarkers for Sport-Related Concussions. Front Neurol. 2018 Apr 12;9:239. doi: 10.3389/fneur.2018.00239. eCollection 2018.
  153. Keshavan, A., et al., Stability of blood-based biomarkers of Alzheimer’s disease over multiple freeze-thaw cycles. Alzheimers Dement (Amst), 2018. 10: p. 448-451.
  154. Khademi M, et al. Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers. PLoS One. 2013 May 7;8(5):e63172.
  155. Khalil M, et al. CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Mult Scler. 2013 Apr;19(4):436-42.
  156. Khalil M, Salzer J. CSF neurofilament light: A universal risk biomarker in multiple sclerosis? Neurology. 2016 Sep 13;87(11):1068-9.
  157. Khalil, M., et al., Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol, 2018. 14(10): p. 577-589.
  158. Kim, W.H., et al., Cerebrospinal fluid biomarkers of neurofibrillary tangles and synaptic dysfunction are associated with longitudinal decline in white matter connectivity: A multi-resolution graph analysis. Neuroimage Clin, 2019. 21: p. 101586.
  159. Koel-Simmelink MJ, et al. The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA. J Immunol Methods. 2014 Jan 15;402(1-2):43-9.
  160. Komori M, et al., Pharmacodynamic effects of daclizumab in the intrathecal compartment. Ann Clin Transl Neurol. 2017 May 29;4(7):478-490. doi: 10.1002/acn3.427. eCollection 2017 Jul.
  161. Korley FK, et al., Performance Evaluation of a Multiplex Assay for Simultaneous Detection of Four Clinically Relevant TBI Biomarkers. J Neurotrauma. 2018 Apr 25. doi: 10.1089/neu.2017.5623. [Epub ahead of print]
  162. Korley FK, et al., Valproic Acid Treatment Decreases Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels in Swine Subjected to Traumatic Brain Injury. J Neurotrauma. 2018 May 15;35(10):1185-1191. doi: 10.1089/neu.2017.5581. Epub 2018 Mar 13.
  163. Korley, F.K., et al., Performance Evaluation of a Multiplex Assay for Simultaneous Detection of Four Clinically Relevant Traumatic Brain Injury Biomarkers. J Neurotrauma, 2018.
  164. Kortvelyessy, P., et al., Biomarkers of Neurodegeneration in Autoimmune-Mediated Encephalitis. Front Neurol, 2018. 9: p. 668.
  165. Kortvelyessy, P., et al., CSF Biomarkers of Neurodegeneration in Progressive Non-fluent Aphasia and Other Forms of Frontotemporal Dementia: Clues for Pathomechanisms? Front Neurol, 2018. 9: p. 504.
  166. Kovacs GG, et al. Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. Eur J Neurol. 2017 Aug 16.
  167. Kovacs GG, et al., Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. Eur J Neurol. 2017 Nov;24(11):1326-e77. doi: 10.1111/ene.13389. Epub 2017 Aug 16.
  168. Kuhle J, et al. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler. 2013 Oct; 19(12):1597-603.
  169. Kuhle J, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. 2016 Oct 1;54(10):1655-61.
  170. Kuhle J, et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology. 2015 Apr 21;84(16):1639-43.
  171. Kuhle J, et al. Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology. 2017 Feb 28;88(9):826-831.
  172. Kuhle J, et al. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Mult Scler. 2016 Oct;22(12):1550-1559.
  173. Kuhle J, et al. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):273-9.
  174. Kuhle Jet al. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta Neurol Scand. 2013 Dec;128(6):e33-6.
  175. Kuhle, J., et al., Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology, 2019. 92(10): p. e1007-e1015.
  176. Lam MA, et al. Absence of systemic oxidative stress and increased CSF prostaglandin F2α in progressive MS. Neurol Neuroimmunol Neuroinflamm. 2016 Jun 30;3(4):e256.
  177. Landqvist Waldö M, et al. Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia.BMC Neurol. 2013 May 29;13:54.
  178. Lewczuk, P., et al., Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease. Alzheimers Res Ther, 2018. 10(1): p. 71.
  179. Li JQ, et al.,  Genome-wide association study identifies two loci influencing plasma neurofilament light levels. Alzheimer’s Disease Neuroimaging Initiative. BMC Med Genomics. 2018 May 10;11(1):47. doi: 10.1186/s12920-018-0364-8.
  180. Li, D.W., et al., Diagnostic Performance of Neurofilaments in Chinese Patients With Amyotrophic Lateral Sclerosis: A Prospective Study. Front Neurol, 2018. 9: p. 726.
  181. Limberg M, Neurofilament Light Chain Determination from Peripheral Blood Samples. Methods Mol Biol. 2016;1304:93-8.
  182. Lin, Y.S., et al., Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. Sci Rep, 2018. 8(1): p. 17368.
  183. Lista S, et al. Alzheimer Precision Medicine Initiative (APMI). Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer’s disease. Neurochem Int. 2017 Sep;108:355-360.
  184. Lista S, et al., Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer’s disease. Alzheimer Precision Medicine Initiative (APMI). Neurochem Int. 2017 Sep;108:355-360. doi: 10.1016/j.neuint.2017.05.010. Epub 2017 May 17.
  185. Ljubenkov, P.A., et al., Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. Ann Clin Transl Neurol, 2018. 5(10): p. 1250-1263.
  186. Ljungqvist J et al. Serum Neurofilament Light Protein as a Marker for Diffuse Axonal Injury: Results from a Case Series Study.J Neurotrauma. 2017 Mar 1;34(5):1124-1127.
  187. Lu CH, et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015 Jun 2;84(22):2247-57.
  188. Lu CH, et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016 Jun 1;3(4):e244.
  189. Lycke J and Zetterberg H. The role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis. Expert Rev Clin Immunol. 2017 Dec;13(12):1143-1153. doi: 10.1080/1744666X.2017.1400380. Epub 2017 Nov 9.
  190. Magdalinou NK, et al. A panel of  nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2015 Nov;86(11):1240-7.
  191. Magnoni S, et al. Tau elevations in the brain extracellular space correlate with reduced amyloid-β levels and predict adverse clinical outcomes after severe traumatic brain injury. Brain. 2012 Apr;135(Pt 4):1268-80.
  192. Mäkitalo S, et al. The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer’s disease. AIDS Res Ther. 2015 Jul 14;12:23.
  193. Marchegiani, F., et al., Diagnostic performance of new and classic CSF biomarkers in age-related dementias. Aging (Albany NY), 2019. 11(8): p. 2420-2429.
  194. Mariotto S, et al., Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status. Mult Scler J Exp Transl Clin. 2017 Nov 22;3(4):2055217317743098. doi: 10.1177/2055217317743098. eCollection 2017 Oct-Dec.
  195. Mariotto, S., et al., Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders. J Neurol Neurosurg Psychiatry, 2019.
  196. Mariotto, S., et al., Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies. J Peripher Nerv Syst, 2018. 23(3): p. 174-177.
  197. Mariotto, S., et al., Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis. J Neurol, 2019.
  198. Marques, T.M., et al., Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls. Mol Neurobiol, 2018.
  199. Marques, T.M., et al., Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology, 2019. 92(13): p. e1479-e1486.
  200. Marrie RA. Serum neurofilament light chain in relapsing-remitting MS: Unchaining disease activity prediction? Neurol Neuroimmunol Neuroinflamm. 2017 Nov 28;5(1):e421. doi: 10.1212/NXI.0000000000000421. eCollection 2018 Jan. No abstract available.
  201. Martínez MA, et al. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler. 2015 Apr;21(5):550-61.
  202. Mattsson N et al. Alzheimer’s Disease Neuroimaging Initiative. Association of Plasma Neurofilament Light WithNeurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. 2017 May 1;74(5):557-566.
  203. Mattsson N, et al. Alzheimer’s Disease Neuroimaging Initiative. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer’s disease. EMBO Mol Med. 2016 Oct 4;8(10):1184-1196.
  204. Mattsson, N., et al., Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol, 2019.
  205. Matute-Blanch C, et al., Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain. 2018 Apr 1;141(4):1085-1093. doi: 10.1093/brain/awy021.
  206. Meeter LHH, et al. Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. Ann Clin Transl Neurol. 2018 Apr 6;5(5):583-597. doi: 10.1002/acn3.559. eCollection 2018 May.
  207. Meeter LHH, et al., Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum.Neurology. 2018 Apr 3;90(14):e1231-e1239. doi: 10.1212/WNL.0000000000005261. Epub 2018 Mar 7.
  208. Melah KE, et al. Cerebrospinal Fluid Markers of Alzheimer’s Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer’s Disease. J Alzheimers Dis. 2016; 50(3):873-86.
  209. Mellergård J, et al. Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis. Eur J Neurol. 2017 Jan;24(1):112-121.
  210. Menke RA, et al. CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol. 2015 Jul;2(7):748-55.
  211. Meregalli, C., et al., Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy. Exp Neurol, 2018. 307: p. 129-132.
  212. Merisson E, et al. Total-tau and neurofilament light in CSF reflect spinal cord ischaemia after endovascular aortic repair.Neurochem Int. 2016 Feb;93:1-5.
  213. Merluzzi, A.P., et al., Differential effects of neurodegeneration biomarkers on subclinical cognitive decline. Alzheimers Dement (N Y), 2019. 5: p. 129-138.
  214. Miller AM, et al. Multicenter immunoassay validation of cerebrospinal fluid neurofilament light: a biomarker for neurodegeneration. Bioanalysis. 2016 Nov;8(21):2243-2254.
  215. Modvig S, et al. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Mult Scler. 2015 Dec;21(14):1761-70.
  216. Modvig S, et al. Cerebrospinal fluid neurofilament light chain levels predict visual outcome after optic neuritis. Mult Scler. 2016 Apr;22(5):590-8.
  217. Modvig S, et al. Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis. PLoS One. 2013 Oct 8;8(10):e77163.
  218. Moreau C, et al., Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis? Antioxid Redox Signal. 2018 Feb 8. doi: 10.1089/ars.2017.7493. [Epub ahead of print]
  219. Moseby-Knappe, M., et al., Serum Neurofilament Light Chain for Prognosis of Outcome After Cardiac Arrest. JAMA Neurol, 2019. 76(1): p. 64-71.
  220. Neselius S, et al. Increased CSF levels of phosphorylated neurofilament heavy protein following bout in amateur boxers. PLoS One. 2013 Nov 15;8(11):e81249.
  221. Neselius S, et al. Monitoring concussion in a knocked-out boxer by CSF biomarker analysis. Knee Surg Sports Traumatol Arthrosc. 2015 Sep;23(9):2536-9.
  222. Neselius S, et al. Neurological assessment and its relationship to CSF biomarkers in amateur boxers. PLoS One. 2014 Jun 18;9(6):e99870.
  223. Niemelä V, et al. Tau or neurofilament light-Which is the more suitable biomarker for Huntington’s disease? PLoS One. 2017 Feb 27;12(2).
  224. Niemelä V, et al., Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington’s disease. PLoS One. 2018 Feb 23;13(2):e0193492. doi: 10.1371/journal.pone.0193492. eCollection 2018.
  225. Niikado, M., et al., Evaluation of Cerebrospinal Fluid Neurofilament Light Chain as a Routine Biomarker in a Memory Clinic. J Gerontol A Biol Sci Med Sci, 2019. 74(4): p. 442-445.
  226. Novakova L, et al. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. J Neurochem. 2016 Oct 27.
  227. Novakova L, et al. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. Mult Scler. 2017 Jan;23(1):62-71.
  228. Novakova L, et al., Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. 2017 Nov 28;89(22):2230-2237. doi: 10.1212/WNL.0000000000004683. Epub 2017 Oct 27.
  229. Novakova L, et al., Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers. PLoS One. 2018 Apr 3;13(4):e0194828. doi: 10.1371/journal.pone.0194828. eCollection 2018.
  230. Oeckl P, et al. Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jul-Aug;17(5-6):404-13.
  231. Olesen, M.N., et al., Cerebrospinal fluid biomarkers for predicting development of multiple sclerosis in acute optic neuritis: a population-based prospective cohort study. J Neuroinflammation, 2019. 16(1): p. 59.
  232. Oliver JM, et al. Effect of Docosahexaenoic Acid on a Biomarker of Head Trauma in American Football. Med Sci Sports Exerc. 2016 Jun;48(6):974-82.
  233. Oliver JM, et al. Serum Neurofilament Light in American Football Athletes over the Course of a Season. J Neurotrauma. 2016 Oct 1;33(19):1784-1789.
  234. Oliver, J.M., et al., Fluctuations in blood biomarkers of head trauma in NCAA football athletes over the course of a season. J Neurosurg, 2018: p. 1-8.
  235. Olsson M, et al., Sleep deprivation and cerebrospinal fluid biomarkers for Alzheimer’s disease. Sleep. 2018 May 1;41(5). doi: 10.1093/sleep/zsy025.
  236. Osborn KE, et al., Cerebrospinal fluid β-amyloid42 and neurofilament light relate to white matter hyperintensities. Neurobiol Aging. 2018 Apr 3;68:18-25. doi: 10.1016/j.neurobiolaging.2018.03.028. [Epub ahead of print]
  237. Parnetti, L., et al., CSF and blood biomarkers for Parkinson’s disease. Lancet Neurol, 2019.
  238. Paterson RW, et al. Dissecting IWG-2 typical and atypical Alzheimer’s disease: insights from cerebrospinal fluid analysis. J Neurol. 2015 Dec;262(12):2722-30.
  239. Paterson RW, et al., Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Alzheimers Res Ther. 2018 Mar 20;10(1):32. doi: 10.1186/s13195-018-0361-3.
  240. Pattinson, C.L., et al., Elevated Tau in Military Personnel Relates to Chronic Symptoms Following Traumatic Brain Injury. J Head Trauma Rehabil, 2019.
  241. Pawlitzki, M., et al., CSF Neurofilament Light Chain Levels in Primary Progressive MS: Signs of Axonal Neurodegeneration. Front Neurol, 2018. 9: p. 1037.
  242. Peluso MJ, et al. Absence of Cerebrospinal Fluid Signs of Neuronal Injury Before and After Immediate Antiretroviral Therapy in Acute HIV Infection. J Infect Dis. 2015 Dec 1;212(11):1759-67.
  243. Peluso MJ, et al. Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis. 2013 Jun 1;207(11):1703-12.
  244. Peng, L., et al., Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease. Mult Scler Relat Disord, 2019. 30: p. 123-128.
  245. Pereira JB, et al. Alzheimer’s Disease Neuroimaging Initiative. Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer’s disease. Neurobiol Aging. 2017 Oct;58:14-29.
  246. Pereira JB, et al., Alzheimer’s Disease Neuroimaging Initiative. Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer’s disease. Neurobiol Aging. 2017 Oct;58:14-29. doi: 10.1016/j.neurobiolaging.2017.06.002. Epub 2017 Jun 17.
  247. Peterson J, et al. Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection. PLoS One. 2014 Dec 26;9(12):e116081.
  248. Petzold A, et al. Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy. J Neurol Sci. 2009 Apr 15;279(1-2):76-9.
  249. Petzold A, et al. Neurofilament ELISA validation. J Immunol Methods. 2010 Jan 31;352(1-2):23-31.
  250. Piehl F, et al. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Mult Scler. 2017 Jun 1.
  251. Pietroboni, A.M., et al., CSF beta-amyloid predicts prognosis in patients with multiple sclerosis. Mult Scler, 2018: p. 1352458518791709.
  252. Pijnenburg YA, et al. Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dement (Amst). 2015 Dec 14;1(4):505-12.
  253. Pinter D, et al., Longitudinal MRI dynamics of recent small subcortical infarcts and possible predictors. J Cereb Blood Flow Metab. 2018 Jan 1:271678X18775215. doi: 10.1177/0271678X18775215. [Epub ahead of print]
  254. Pinter, D., et al., Longitudinal MRI dynamics of recent small subcortical infarcts and possible predictors. J Cereb Blood Flow Metab, 2018: p. 271678×18775215.
  255. Poesen K, et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017 Jun 13;88(24):2302-2309.
  256. Poesen, K. and P. Van Damme, Diagnostic and Prognostic Performance of Neurofilaments in ALS. Front Neurol, 2018. 9: p. 1167.
  257. Posti, J.P., et al., Correlation of Blood Biomarkers and Biomarker Panels with Traumatic Findings on Computed Tomography after Traumatic Brain Injury. J Neurotrauma, 2019.
  258. Preische, O., et al., Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat Med, 2019. 25(2): p. 277-283.
  259. Puz P, et al., Diagnostic methods used in searching for markers of atrophy in patients with multiple sclerosis. Neurol Res. 2018 Feb;40(2):110-116. doi: 10.1080/01616412.2017.1403729. Epub 2017 Nov 23.
  260. Pyykkö OT, et al. Cerebrospinal fluid biomarker and brain biopsy findings in idiopathic normal pressure hydrocephalus. PLoS One. 2014 Mar 17;9(3):e91974.
  261. Quintana, E., et al., Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain. Eur J Neurol, 2018. 25(9): p. 1189-1191.
  262. Racine AM, et al. Association of longitudinal white matter degeneration and cerebrospinal fluid biomarkers of neurodegeneration, inflammation and Alzheimer’s disease in late-middle-aged adults. Brain Imaging Behav. 2017 Jun 9.
  263. Racine AM, et al. Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer’s Disease. J Alzheimers Dis. 2016 Oct 18;54(4):1395-1408.
  264. Racine AM, et al. Cerebrospinal fluid ratios with Aβ42 predict preclinical brain β-amyloid accumulation. Alzheimers Dement (Amst). 2016;2:27-38.
  265. Ragnarsson O, et al. Neurodegenerative and inflammatory biomarkers in cerebrospinal fluid in patients with Cushing’s syndrome in remission. Eur J Endocrinol. 2013 Jul 6;169(2):211-5.
  266. Rana OR, et al. Neurofilament light chain as an early and sensitive predictor of long-term neurological outcome in patients after cardiac arrest. Int J Cardiol. 2013 Sep 30;168(2):1322-7.
  267. Reid SJ, et al. Alzheimer’s disease markers in the aged sheep (Ovis aries). Neurobiol Aging. 2017 Oct;58:112-119.
  268. Reid SJ, et al., Alzheimer’s disease markers in the aged sheep (Ovis aries). Neurobiol Aging. 2017 Oct;58:112-119. doi: 10.1016/j.neurobiolaging.2017.06.020. Epub 2017 Jun 24.
  269. Reinsfelt B, et al. Cerebrospinal fluid markers of brain injury, inflammation, and blood-brain barrier dysfunction in cardiac surgery. Ann Thorac Surg. 2012 Aug;94(2):549-55.
  270. Reus, L.M., et al., Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change. J Psychiatr Res, 2018. 104: p. 183-191.
  271. Ridler C. Prion disease: Dramatic increases in blood levels of tau and neurofilament light in patients with prion disease. Nat Rev Neurol. 2018 May;14(5):252. doi: 10.1038/nrneurol.2018.34. Epub 2018 Mar 16. No abstract available.
  272. Ridler, C., Prion disease: Dramatic increases in blood levels of tau and neurofilament light in patients with prion disease. Nat Rev Neurol, 2018. 14(5): p. 252.
  273. Rodrigues FB, et al. Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington’s Disease. PLoS One. 2016 Sep 22;11(9).
  274. Rohrer JD, et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia.Neurology. 2016 Sep 27;87(13):1329-36.
  275. Rojas JC, et al. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol. 2016 Feb 1;3(3):216-25.
  276. Rojas JC, et al., CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. 2018 Jan 23;90(4):e273-e281. doi: 10.1212/WNL.0000000000004859. Epub 2017 Dec 27.
  277. Rolstad S, et al. Cognitive performance and cerebrospinal fluid biomarkers of neurodegeneration: a study of patients with bipolar disorder and healthy controls. PLoS One. 2015 May 8;10(5).
  278. Rolstad S, et al. Differential Impact of Neurofilament Light Subunit on Cognition and Functional Outcome in Memory Clinic Patients with and without Vascular Burden. J Alzheimers Dis. 2015;45(3):873-81.
  279. Romme Christensen J, et al. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial.Neurology. 2014 Apr 29;82(17):1499-507.
  280. Romme Christensen, J., et al., CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage. Mult Scler, 2018: p. 1352458518774880.
  281. Rosén C, et al. Cerebrospinal fluid biomarkers in cardiac arrest survivors. Resuscitation. 2014 Feb;85(2):227-32.
  282. Rossi D, et al., CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J Neurol. 2018 Mar;265(3):510-521. doi: 10.1007/s00415-017-8730-6. Epub 2018 Jan 10.
  283. Rostgaard N, et al., CSF neurofilament light concentration is increased in presymptomatic CHMP2B mutation carriers.Neurology. 2018 Jan 9;90(2):e157-e163. doi: 10.1212/WNL.0000000000004799. Epub 2017 Dec 13.
  284. Rubin, L.H., et al., NFL blood levels are moderated by subconcussive impacts in a cohort of college football players. Brain Inj, 2019. 33(4): p. 456-462.
  285. Salzer J, et al. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler. 2010 Mar;16(3):287-92.
  286. Sanchez-Valle, R., et al., Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease. Alzheimers Res Ther, 2018. 10(1): p. 113.
  287. Sandberg L, et al. Vitamin D and axonal injury in multiple sclerosis. Mult Scler. 2016 Jul;22(8):1027-31.
  288. Sandelius Å, et al., Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology. 2018 Feb 6;90(6):e518-e524. doi: 10.1212/WNL.0000000000004932. Epub 2018 Jan 10.
  289. Scarafino, A., et al., Diagnostic and prognostic power of CSF Tau in amyotrophic lateral sclerosis. J Neurol, 2018. 265(10): p. 2353-2362.
  290. Scherling CS, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration.Ann Neurol. 2014 Jan;75(1):116-26.
  291. Schreiber, S., et al., Significance of CSF NfL and tau in ALS. J Neurol, 2018. 265(11): p. 2633-2645.
  292. Scott G, et al., Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration. Brain. 2018 Feb 1;141(2):459-471. doi: 10.1093/brain/awx339.
  293. Sellebjerg F, et al. Defining active progressive multiple sclerosis. Mult Scler. 2017 Aug 1.
  294. Sellebjerg F, et al., Defining active progressive multiple sclerosis. Mult Scler. 2017 Nov;23(13):1727-1735. doi: 10.1177/1352458517726592. Epub 2017 Aug 23.
  295. Sellebjerg, F., et al., Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis. Mult Scler, 2018: p. 1352458518794308.
  296. Shah DK, et al., Raised Plasma Neurofilament Light Protein Levels Are Associated with Abnormal MRI Outcomes in Newborns Undergoing Therapeutic Hypothermia. Front Neurol. 2018 Mar 5;9:86. doi: 10.3389/fneur.2018.00086. eCollection 2018.
  297. Shahim P, et al. Cerebrospinal fluid braininjury biomarkers in children: a multicenter study. Pediatr Neurol. 2013 Jul;49(1):31-39.e2.
  298. Shahim P, et al. Cerebrospinal fluid markers of central nervous system injury in decompression illness – a case-controlled pilot study. Diving Hyperb Med. 2015 Dec;45(4):240-3.
  299. Shahim P, et al. Neurochemical Aftermath of Repetitive Mild Traumatic Brain Injury. JAMA Neurol. 2016 Nov 1;73(11):1308-1315.
  300. Shahim P, et al. Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. Neurology. 2017 May 9;88(19):1788-1794.
  301. Shahim P, et al. Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. Sci Rep. 2016 Nov 7;6:36791.
  302. Shahim P, et al., Neurofilament light and tau as blood biomarkers for sports-related concussion. Neurology. 2018 May 15;90(20):e1780-e1788. doi: 10.1212/WNL.0000000000005518. Epub 2018 Apr 13.
  303. Shahim, P., et al., Neurofilament light and tau as blood biomarkers for sports-related concussion. Neurology, 2018. 90(20): p. e1780-e1788.
  304. Siller N, et al., Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.Mult Scler. 2018 Mar 1:1352458518765666. doi: 10.1177/1352458518765666. [Epub ahead of print]
  305. Skillbäck T, et al. Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples.Alzheimers Res Ther. 2013 Oct 14;5(5):47.
  306. Skillbäck T, et al. Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Aug;18(5-6):397-403.
  307. Skillbäck T, et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology. 2014 Nov 18;83(21):1945-53.
  308. Skillbäck T, et al. CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. Neurobiol Aging. 2017 Jul 11;59:1-9.
  309. Skillbäck T, et al., Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Aug;18(5-6):397-403. doi: 10.1080/21678421.2017.1281962. Epub 2017 Feb 6.
  310. Skillbäck T, et al., CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. Neurobiol Aging. 2017 Nov;59:1-9. doi: 10.1016/j.neurobiolaging.2017.06.028. Epub 2017 Jul 11.
  311. Soylu-Kucharz R, et al., Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington’s disease R6/2 mice. Sci Rep. 2017 Oct 26;7(1):14114. doi: 10.1038/s41598-017-14179-1.
  312. Sprecher KE, et al. Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults. Neurology. 2017 Aug 1.
  313. Sprecher KE, et al., Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults. Neurology. 2017 Aug 1;89(5):445-453. doi: 10.1212/WNL.0000000000004171. Epub 2017 Jul 5.
  314. Staffaroni, A.M., et al., Association of Blood and Cerebrospinal Fluid Tau Level and Other Biomarkers With Survival Time in Sporadic Creutzfeldt-Jakob Disease. JAMA Neurol, 2019.
  315. Startin, C.M., et al., Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease. Alzheimers Res Ther, 2019. 11(1): p. 26.
  316. Steinacker P, et al. Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1-2):112-119.
  317. Steinacker P, et al. Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. Neurology. 2017 Mar 7;88(10):961-969.
  318. Steinacker P, et al. Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Sci Rep. 2016 Dec 8;6:38737.
  319. Steinacker P, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):12-20.
  320. Steinacker, P., et al., Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology, 2018. 91(15): p. e1390-e1401.
  321. Stilund M, et al. A multi-biomarker follow-up study of patients with multiple sclerosis. Brain Behav. 2016 Jul 11;6(9).
  322. Stilund M, et al. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel. PLoS One. 2015 Apr 10;10(4):e0119681.
  323. Strydom A, et al., LonDownS Consortium. Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome. Alzheimers Res Ther. 2018 Apr 10;10(1):39. doi: 10.1186/s13195-018-0367-x.
  324. Sun B, et al., Blood neuron-derived exosomes as biomarkers of cognitive impairment in HIV. AIDS. 2017 Sep 10;31(14):F9-F17. doi: 10.1097/QAD.0000000000001595.
  325. Szejko, N., et al., Quantification of the Light Subunit of Neurofilament Protein in Cerebrospinal Fluid of Huntington’s Disease Patients. PLoS Curr, 2018. 10.
  326. Tejeda-Velarde A, et al., Clinical usefulness of prognostic biomarkers in optic neuritis. Eur J Neurol. 2018 Apr;25(4):614-618. doi: 10.1111/ene.13553. Epub 2018 Feb 6.
  327. Teunissen CE, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology. 2009 Apr 14;72(15):1322-9.
  328. Tiedt, S., et al., Serum neurofilament light: A biomarker of neuroaxonal injury after ischemic stroke. Neurology, 2018. 91(14): p. e1338-e1347.
  329. Toorell H, et al. Increase of neuronal injury markers Tau and neurofilament light proteins in umbilical blood after intrapartum asphyxia. J Matern Fetal Neonatal Med. 2017 Jul 9:1-5.
  330. Toorell H, et al., Increase of neuronal injury markers Tau and neurofilament light proteins in umbilical blood after intrapartum asphyxia. J Matern Fetal Neonatal Med. 2018 Sep;31(18):2468-2472. doi: 10.1080/14767058.2017.1344964. Epub 2017 Jul 9.
  331. Tortelli R, et al. Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis. Eur J Neurol. 2015 Jan;22(1):215-8.
  332. Tortelli R, et al. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol. 2012 Dec;19(12):1561-7.
  333. Tortorella C, et al. Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of multiple sclerosis.Mult Scler. 2015 Apr;21(4):396-401.
  334. Tortorella C, et al. Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler. 2017 May 1.
  335. Traenka C, et al. Serum Neurofilament Light Chain Levels Are Associated with Clinical Characteristics and Outcome in Patients with Cervical Artery Dissection. Cerebrovasc Dis. 2015;40(5-6):222-7.
  336. Trentini A, et al. N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. J Neurol. 2014 Dec;261(12):2338-43.
  337. Ulfhammer, G., et al., Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment. Aids, 2018. 32(15): p. 2171-2178.
  338. Vågberg M, et al. Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction. PLoS One. 2015 Aug 28;10(8):e0135886.
  339. van der Vuurst de Vries, R.M., et al., High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome. Mult Scler, 2018: p. 1352458518775303.
  340. van Eijk JJ, et al. CSF neurofilament proteins levels are elevated in sporadic Creutzfeldt-Jakob disease. J Alzheimers Dis. 2010;21(2):569-76.
  341. van Lieverloo, G.G.A., et al., Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst, 2019.
  342. van Zoest RA, et al.,  Structural Brain Abnormalities in Successfully Treated HIV Infection: Associations With Disease and Cerebrospinal Fluid Biomarkers. Comorbidity in Relation to AIDS (COBRA) Collaboration. J Infect Dis. 2017 Dec 27;217(1):69-81. doi: 10.1093/infdis/jix553.
  343. Varhaug KN, et al., Neurofilament light chain predicts disease activity in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm. 2017 Nov 28;5(1):e422. doi: 10.1212/NXI.0000000000000422. eCollection 2018 Jan.
  344. Varhaug, K.N., et al., Neurofilament Light Chain as a Biomarker in Multiple Sclerosis. Front Neurol, 2019. 10: p. 338.
  345. Verde, F., et al., Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry, 2019. 90(2): p. 157-164.
  346. Vijverberg EG, et al. Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders. Alzheimers Dement (Amst). 2017 Mar 2;7:99-106.
  347. Villar LM, et al. Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis. Eur J Neurol. 2015 Aug;22(8):1169-75.
  348. Vinther-Jensen T, et al. Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease.Neurol Neuroimmunol Neuroinflamm. 2016 Sep 28;3(6).
  349. Wallace, C., et al., Heading in soccer increases serum neurofilament light protein and SCAT3 symptom metrics. BMJ Open Sport Exerc Med, 2018. 4(1): p. e000433.
  350. Wallace, C., et al., No change in plasma tau and serum neurofilament light concentrations in adolescent athletes following sport-related concussion. PLoS One, 2018. 13(10): p. e0206466.
  351. Wallin A, et al. Progression from mild to pronounced MCI is not associated with cerebrospinal fluid biomarker deviations.Dement Geriatr Cogn Disord. 2011;32(3):193-7.
  352. Wellington H, et al., CSF neurogranin or tau distinguish typical and atypical Alzheimer disease. Ann Clin Transl Neurol. 2018 Jan 11;5(2):162-171. doi: 10.1002/acn3.518. eCollection 2018 Feb.
  353. Weston PSJ, et al., Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. Neurology. 2017 Nov 21;89(21):2167-2175. doi: 10.1212/WNL.0000000000004667. Epub 2017 Oct 25.
  354. Weston, P.S.J., et al., Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease. Alzheimers Res Ther, 2019. 11(1): p. 19.
  355. Weydt P, et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis.Ann Neurol. 2016 Jan;79(1):152-8.
  356. Wild EJ, et al. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington’s disease patients. J Clin Invest. 2015 May;125(5):1979-86.
  357. Wilke C, et al. Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1270-1272.
  358. Wilke C, et al., Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study. J Neurol. 2018 May 8. doi: 10.1007/s00415-018-8893-9. [Epub ahead of print]
  359. Wilke, C., et al., Serum neurofilament light chain is increased in hereditary spastic paraplegias. Ann Clin Transl Neurol, 2018. 5(7): p. 876-882.
  360. Wilke, C., et al., Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study. J Neurol, 2018. 265(7): p. 1618-1624.
  361. Wirsching, A., et al., Association of Acute Increase in Plasma Neurofilament Light with Repetitive Subconcussive Head Impacts: A Pilot Randomized Control Trial. J Neurotrauma, 2019. 36(4): p. 548-553.
  362. Wright PW, et al. Putamen volume and its clinical and neurological correlates in primary HIV infection. AIDS. 2016 Jul 17;30(11):1789-94.
  363. Yildiz, O., et al., Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine. Mult Scler Relat Disord, 2018. 24: p. 20-27.
  364. Yilmaz A, et al. Neurofilament light chain protein as amarker of neuronal injury: review of its use in HIV-1 infection and referencevalues for HIV-negative controls. Expert Rev Mol Diagn. 2017 Aug;17(8):761-770.
  365. Yilmaz A, et al., Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Rev Mol Diagn. 2017 Aug;17(8):761-770. doi: 10.1080/14737159.2017.1341313. Epub 2017 Jun 14.
  366. Zanier ER, et al. Neurofilament light chain levels in ventricular cerebrospinal fluid after acute aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 2011 Feb;82(2):157-9.
  367. Zeitlberger, A.M., et al., Plasma Markers of Neurodegeneration Are Raised in Friedreich’s Ataxia. Front Cell Neurosci, 2018. 12: p. 366.
  368. Zerr I, et al., Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimers Dement. 2018 Feb 3. pii: S1552-5260(18)30002-5. doi: 10.1016/j.jalz.2017.12.008. [Epub ahead of print]
  369. Zetterberg H, et al. Alzheimer’s Disease Neuroimaging Initiative. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. JAMA Neurol. 2016 Jan;73(1):60-7.
  370. Zetterberg H. Fluid biomarkers for microglial activation and axonal injury in multiple sclerosis. Acta Neurol Scand. 2017 Nov;136 Suppl 201:15-17. doi: 10.1111/ane.12845. Review.
  371. Zetterberg H. Neurofilament Light: A Dynamic Cross-Disease Fluid Biomarker for Neurodegeneration. Neuron. 2016 Jul 6;91(1):1-3.
  372. Zetterberg, H. and A. Svenningsson, Serum neurofilament light and prediction of multiple sclerosis in clinically isolated syndrome. Neurology, 2019. 92(7): p. 313-314.
  373. Zhao, Y., et al., Neurofilament light chain protein in neurodegenerative dementia: A systematic review and network meta-analysis. Neurosci Biobehav Rev, 2019. 102: p. 123-138.